New Drug From Daiichi Sankyo Boosts Japan's OTC Market
This article was originally published in PharmAsia News
In 2007, the Japanese OTC market grew by 2.3 percent to ¥700 billion, a reversal from a downward trend in recent years. New drugs such as Daiichi Sankyo's Transino contributed to the growth. A liver spots improving drug, Transino has activated the market for products treating pigment spots with sales increasing from ¥10 billion to ¥17 billion. Next year, Tokyo based SSP, a subsidiary of Boehringer Ingelheim, will market drugs made of western herbs such as gingko biloba and grape leaves. Taisho Pharmaceuticals also signed contacts with a German company to introduce similar products. (Click here for more - Japanese language
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.